Ositag

Ositag is Osimertinib, a third-generation EGFR tyrosine kinase inhibitor. It is indicated for EGFR mutation-positive NSCLC, including T790M-positive disease and works by selectively inhibiting sensitizing and resistance-associated EGFR mutations.

Features